| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5119 | Tgx-155 | Potent and selective inhibitor of PI 3-K |
|
| DCC5120 | Th1027 | Novel highly potent and specific inhibitor of TLR8, targeting an unconventional pocket on the TLR8 protein-protein Interface |
|
| DCC5121 | Thaigranatin T | Natural potent human carboxylesterase 2 (hCES2) inhibitor (IC50: 5.05 μM) |
|
| DCC5122 | Thalassosamide | Natural antibiotic, being active against P. aeruginosa both in vitro and in vivo. |
|
| DCC5123 | Thdp-17 | Novel glutaminase activity inhibitor, showing a partial uncompetitive inhibition in vitro and a significant reduction of ammonia and glutamate production in vivo |
|
| DCC5124 | Thiamphenicol Palmitate | Prodrug of Thiamphenicol, inhibiting the 50S subunit of the bacterial ribosome and protein translation |
|
| DCC5125 | Thiazolidinedione-8 | Novel antibiofilm agent, disturbing symbiotic balance between C. albicans and S. mutans in dual species biofilm |
|
| DCC5126 | Thidiazuron | Highly efficient bioregulator of plant morphogenesis in the tissue culture technique, inducing diverse responses ranging from induction of callus to embryogenesis or organogenesis, acting through modulation of the endogenous plant growth regulators, modif |
|
| DCC5127 | Thielocin B1 | Novel protein-protein interaction inhibitor of PAC3 homodimer |
|
| DCC5128 | Thiobenzanilide 63t | Novel selective anticancer agent, selectively inducing cancer cell death in a caspase independent pathway |
|
| DCC5129 | Thiocrom-31 | First-in-class potent, selective, reversible, and tight binding inhibitor of human monoamine oxidase B (hMAO-B) (hMAO-B IC 50 = 1.52 ± 0.15 nM) |
|
| DCC5130 | Thioguanine-18 | Novel potent DENV2-NS2B/NS3pro inhibitor |
|
| DCC5131 | Thioluciferin | Firefly luciferin analog as a key element of bioluminescent reporters for oxidation state and thiol/disulfide equilibria |
|
| DCC5132 | Thiomuscimol Hydrobromide | GABAA receptor agonist |
|
| DCC5133 | Thiowurtzine | Novel Potent Inhibitor of the Opioid Receptors and the Ion Channels |
|
| DCC5134 | Thioxodihydroquinazolinone-19 | Novel inducer of apoptotic cell death in platinum-resistant A2780cis human ovarian cancer cells, exhibitong a strong inhibitory effect in ovarian CSC-LCs in combination with cisplatin |
|
| DCC5135 | Thiq-20c | Steroidomimetic and Chimeric Microtubule Disruptor |
|
| DCC5136 | Thk-523 | Selective Tau ligand, selectively binding to neurofibrillary tangles and neuropils in people with Alzheimer's disease |
|
| DCC5137 | Th-pf01 | Novel orthosteric-allosteric dual inhibitor of PfHT1 as selective antimalarial agent |
|
| DCC5138 | Th-pf02 | Novel orthosteric-allosteric dual inhibitor of PfHT1 as selective antimalarial agent |
|
| DCC5139 | Th-pf03 | Novel orthosteric-allosteric dual inhibitor of PfHT1 as selective antimalarial agent |
|
| DCC5140 | Thpp-11f | Novel potent, highly selective and orally available PI3Kδ inhibitor |
|
| DCC5141 | Thpp-2 | Novel phosphodiesterase 10A (PDE10A) inhibitor for treatment of schizophrenia |
|
| DCC5142 | Thpp-4 | Phosphodiesterase 10A (PDE10A) inhibitor |
|
| DCC5143 | Thr101 | Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9; NOX Inhibitor |
|
| DCC5144 | Thrombin-in-3g | Novel selective thrombin inhibitor, inducing conformational allostery |
|
| DCC5145 | Thrx160209 | Novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor |
|
| DCC5146 | Tiagabine | Anti-epileptic and anticonvulsant agent, acting as a selective GABA reuptake inhibitor |
|
| DCC5147 | Tiancimycin | Anthraquinone-fused enediyne antitumor agent for development of antibody-drug conjugates (ADCs) |
|
| DCC5148 | Tiemonium Iodide | Muscarinic receptor antagonist, anticholinergic,and parasympatholytic |
|
